We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) Captopril 25mg/5mL Sugar free oral solution (Syrimed)
Section 19A approved medicine
(Approval lapsed) Captopril 25mg/5mL Sugar free oral solution (Syrimed)
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0422 429 648
Approved until
Status
Expired
Medicines in short supply/unavailable
CAPOTEN captopril 5mg/mL oral liquid bottle - ARTG 68962
Indication(s)
HYPERTENSION: Captopril is indicated for the treatment of hypertension.
In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis.
Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive.
MYOCARDIAL INFARCTION: Captopril is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40% and to reduce the incidence of overt heart failure, and subsequent hospitalisations for congestive heart failure in these patients. The efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct.
HEART FAILURE: Captopril is indicated for the treatment of heart failure. In symptomatic patients it is recommended that captopril be administered together with a diuretic.
DIABETIC NEPHROPATHY: Captopril is indicated for the treatment of diabetic nephropathy in patients with Type 1 insulin-dependent diabetes mellitus.
Images
